Synonyms: Compound S-D1 [WO2021155225A1] | FHD609
Compound class:
Synthetic organic
Comment: FHD-609 is a PROTAC degrader of bromodomain-containing protein 9 (BRD9), that was designed as a treatment for synovial sarcoma and SMARCB1-loss tumours. It is one of the compounds claimed in Foghorn Therapeutics' patent WO2021155225A1 [1]. FHD-609 is suitable for intravenous delivery.
|
|
No information available. |
Summary of Clinical Use ![]() |
FHD-609 has progressed to the initial stage of clinical evaluation. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Phase 1 Interventional | Foghorn Therapeutics Inc. |